Email updates

Keep up to date with the latest news and content from BMC Chemical Biology and BioMed Central.

Open Access Highly Accessed Research article

Synthesis and cytotoxicity of a biotinylated CC-1065 analogue

Yuqiang Wang*, Huiling Yuan, Susan C Wright, Hong Wang and James W Larrick

Author Affiliations

Panorama Research, Inc., 2462 Wyandotte Stree, Mountain View, California, 94043, USA

For all author emails, please log on.

BMC Chemical Biology 2002, 2:1  doi:10.1186/1472-6769-2-1

Published: 28 January 2002



The use of pretargeting technology for cancer imaging and treatment has made significant progress in the last few years. This approach takes advantage of the fact that biotin binds strongly to proteins avidin and streptavidin. Thus, a non-toxic tumor cell specific antibody is conjugated with avidin/streptavidin, and is administered to patients. After the antibody binds to tumor cells (usually 24–48 h); a clearing agent is given to remove the residual circulating antibodies in blood. Lastly, a toxic biotin-radioisotope conjugate is administered. Due to the small size of the biotin-radioisotope molecule and tight binding between biotin and avidin/streptavidin, the biotin-radioisotope rapidly binds to tumor cells with high specificity. CC-1065 (1) is one of a few classes of extremely potent antitumor agents, and a biotinalyted CBI-bearing CC-1065 analogue is a promising candidate to be used in the pretargeting technology to treat cancer.


A biotinalyted CBI-bearing CC-1065 analogue, 6, was synthesized. The IC50 of 6 was 0.7 nM against U937 cells. Compound 6 caused apototsis of U937 cells.


For the first time, a biotinalyted CBI-bearing CC-1065 analogue, 6, was synthesized. The biotinylated 6 can serve as a model compound to explore the usefulness of non-radioactive small molecule anticancer drugs in the pretargeting strategy for cancer imaging and therapy.